Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cladribine Dose Escalation in Conditioning for Refractory Leukemia/MDS
NCT03235973Phase 1Unknown
- Sponsor
- Institut Paoli-Calmettes
- Start
- Apr 2018
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cladribine in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS), sponsored by Institut Paoli-Calmettes. Primary endpoint: Maximal Tolerable Dose at 30 days. Status: unknown.
02
Drugs
cladribine
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT03235973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03235973.